Drugs

A paper at the National Bureau of Economics examines how quickly changes in medical knowledge diffuse into practice.

According to a study, the price of treating multiple sclerosis with self-administered drugs increased more than four times between 2006 and 2016.

Prices for generic drugs have actually fallen fairly rapidly in recent years, according to a study from the National Bureau of Economic Research.

A paper from the Pacific Research Group finds that there are large potential savings from more, and more use of, biosimilars.

An IQVIA report evaluates the pipeline for cancer therapies.

A brief from the Kaiser Family Foundation describes prescription drug spending by payer type.

A large health plan's program in incentivize doctors to use lower-cost oncology drugs shows little results.

IQVIA gives us its annual forecasting on prescription drug use for the next few years.

Using international reference pricing for drugs would save the United States a lot of money.

A GoodRx report describes drug pricing trends.

An article in Health Affairs proposes a standard for evaluating the "fairness" of drug pricing.

A new analysis finds that just a few drugs account for much of the growth in Medicare Part D spending.